Functinal analysis of Glypican-1 in cancer stem-like cells and developmnt of antibody-based therapy

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07732
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Iwate Medical University (2021); Kochi University (2019)
• Principal Investigator: Serada Satoshi 岩手医科大学, 医歯薬総合研究所, 准教授 (50463302)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 癌 / 抗体医薬

Outline of Final Research Achievements

Cancer stem cell is thought to be involved in the cause of chemoresistance in cancer. Therefore, targeting cancer stem cell might be an effective therapy for eradication of cancer. In this study, we confirmed that enhanced expression of Glypican-1 (GPC1) in the enriched fraction of cancer stem cells from esophageal squamous cell carcinoma cell line. Under the 3D-culture condition, GPC1 targeted antibody-drug conjugate (ADC) exhibited potent growth inhibitory effect against cancer stem cell enriched cells in vitro. GPC1-ADC potentially represent antitumor effect against cancer stem cells and would be a promising approach for the treatment of cancer.

Free Research Field

腫瘍治療学

Academic Significance and Societal Importance of the Research Achievements

癌幹細胞は癌の再発の原因の1つと考えられている。食道癌由来TE8細胞から癌幹細胞の活性が高い集団を濃縮した。この細胞集団に癌抗原であるGlypican-1(GPC1)が高発現することを明らかにした。さらに、GPC1を標的とした抗体薬物複合体が癌幹細胞を濃縮した細胞に強い細胞増殖阻害活性を示すことを明らかにした。GPC1を標的とした抗体医薬は将来、癌に対する新規治療薬になり得る可能性が示唆された。